Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.306
+0.116 (3.65%)
Feb 24, 2026, 10:33 AM EST - Market open
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
11.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | 500.00K | - | - |
| Dec 31, 2019 | 500.00K | - | - |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | 500.00K | - | - |
| Dec 31, 2016 | 500.00K | - | - |
| Dec 31, 2015 | 500.00K | - | - |
| Dec 31, 2014 | 500.00K | - | - |
| Dec 31, 2013 | 500.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 2.00M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 2.50M | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| CytoMed Therapeutics | 573.19K |
| Iterum Therapeutics | 390.00K |
| Pulmatrix | 3.00K |
| BioCardia | 3.00K |
| Soligenix | 2.34K |
IMNN News
- 19 days ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 2 months ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 3 months ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript - Seeking Alpha
- 3 months ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire
- 3 months ago - IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer - GlobeNewsWire